This phase III trial is evaluating the safety and effectiveness of two oral drugs (abiraterone alone and in combination with olaparib) in patients with metastatic castration-resistant prostate cancer (mCRPC) who have received no prior chemotherapy or new hormonal therapies.
This trial is treating patients with metastatic castration resistant prostate cancer.
This is a systemic therapy trial.
You may be able to join this trial if:
- You are able to swallow medication by mouth.
- You have been diagnosed with cancer, but have not received any treatment.
- Your cancer has spread to other parts of the body.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have been diagnosed with a prior or secondary type of cancer.
- You have had certain treatments, surgical procedures or drugs.
- You have previously been treated (or are currently being treated) on a clinical trial.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Scientific Title
A Randomised, Double-blind, Placebo-controlled, Multicentre Phase III Study of Olaparib Plus Abiraterone Relative to Placebo Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer
Commercial Sponsor
AstraZeneca
Summary
Participants in this trial will be randomised to receive either olaparib or a placebo as a 100mg or 150mg tablet, in combination with abiraterone (1000mg once daily) and prednisone or prednisolone (5mg twice daily).
Recruiting Hospitals Read More